Q3 Earnings Forecast for GLSI Issued By Noble Financial

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Investment analysts at Noble Financial issued their Q3 2025 earnings per share estimates for Greenwich LifeSciences in a research note issued to investors on Wednesday, August 20th. Noble Financial analyst R. Leboyer anticipates that the company will earn ($0.36) per share for the quarter. Noble Financial has a “Outperform” rating and a $45.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.80) per share. Noble Financial also issued estimates for Greenwich LifeSciences’ Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at $3.98 EPS and FY2029 earnings at $9.90 EPS.

Greenwich LifeSciences Price Performance

NASDAQ:GLSI opened at $12.18 on Friday. The company has a market cap of $166.01 million, a price-to-earnings ratio of -8.96 and a beta of 1.65. The stock’s 50 day simple moving average is $10.80 and its two-hundred day simple moving average is $10.59. Greenwich LifeSciences has a 1 year low of $8.06 and a 1 year high of $16.50.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06).

Institutional Trading of Greenwich LifeSciences

Hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN lifted its position in shares of Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock valued at $32,000 after acquiring an additional 1,008 shares in the last quarter. Barclays PLC grew its stake in shares of Greenwich LifeSciences by 12.7% in the fourth quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after buying an additional 1,088 shares in the last quarter. GAMMA Investing LLC purchased a new position in Greenwich LifeSciences in the first quarter valued at $126,000. Bank of America Corp DE lifted its holdings in Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after buying an additional 1,322 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Greenwich LifeSciences by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock worth $1,261,000 after buying an additional 1,972 shares during the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.